|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||14.17 - 14.54|
|52 Week Range||8.31 - 32.74|
|PE Ratio (TTM)||-3.56|
|Dividend & Yield||0.00 (0.00%)|
|1y Target Est||N/A|
Let’s just get this out of the way: Trading a stock as volatile as Valeant Pharmaceuticals Intl Inc (NYSE:VRX) is a gamble, not an investment. VRX stock is down 40% in 12 months, but it’s almost flat this year. Recently, Valeant had a 20% correction in as many days, which makes for a scary knife to catch.
The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Index (PMI) data, output in the Healthcare sector is rising.
For his 'Executive Decision' segment, Cramer again sat down with Joe Papa, chairman and CEO of Valeant